Factors affecting antiretroviral therapy adherence among HIV-positive pregnant and postpartum women: An adapted systematic review

International Journal of STD and AIDS

Volumn 24, Issue 6, 2013, Pages 427-432

  Vitalis, D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; AIDS; antiretroviral therapy; ART; HIV; postpartum; pregnant; women

Indexed keywords

ANTIRETROVIRUS AGENT;

CHILD HEALTH; DEPRESSION; DRUG SAFETY; FEAR; FINANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; MATERNAL AGE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POVERTY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROGENY; PUERPERIUM; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RELIGION; REVIEW; RISK FACTOR; SELF CONCEPT; SOCIAL SUPPORT; SYSTEMATIC REVIEW; TERATOGENESIS; VIOLENCE; VITAMIN SUPPLEMENTATION;

ADHERENCE; AIDS; ANTIRETROVIRAL THERAPY; ART; HIV; POSTPARTUM; PREGNANT; WOMEN;

ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84887386231     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462412472807     Document Type: Review

References (57)

1. DiMatteo MR.Variations to patients' adherence to medical recommendations: a quantitative review of 50 years of research.Med Care. 2004;42:200-9.
2. Morisky DE,Green LW,Levine DM.Concurrent and predictive validity of a self-reported measure of medication adherence.Med Care. 1986;24:67-74.
3. Chesney M.Adherence to HAART regimens.AIDS Patient Care STDS. 2003;17:169-77.
4. Paterson DL,Swindells S,Mohr J, et al.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.Ann Intern Med. 2000;133:21-30.
5. Turner BJ.Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients.J Infect Dis. 2002;185:143-51.
6. Bangsberg DR.Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression.Clin Infect Dis. 2006;43:939-41.
7. Battaglioli-DeNero AM.Strategies for improving patient adherence to therapy and long-term patient outcomes.J Assoc Nurses AIDS Care. 2007;18:S17-22.
8. Newell ML.Current issues in the prevention of mother-to-child transmission of HIV-1 infection.Trans R Soc Trop Med Hyg. 2006;100:1-5.
9. World Health Organization. PMTCT Strategic Vision 2010-2015: Preventing Mother-to-child Transmission of HIV to Reach the UNGASS Millennium Goals. 2010. See See http://whqlibdoc.who.int/publications/2010/9789241599030_eng.pdf(accessed May 2011).
10. Sethi AK,Celentano DD,Gange SJ,Moore RD,Gallant JE.Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.Clin Infect Dis. 2003;37:1112-8.
11. Barclay TR,Hinkin CH,Castellon SA, et al.Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status.Health Psychol. 2007;26:40-9.
12. Poppa A,Davidson O,Deutsch J, et al.British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) Guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003).HIV Med. 2004;5:46-60.
13. Horne R,Cooper V,Gellaitry G,Date HL,Fisher M.Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework.J Acquir Immune Defic Syndr. 2007;45:334-41.
14. Horne R,Weinman J.Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.J Psychosom Res. 1999;47:555-67.
15. Horne R.Patients' beliefs about treatment: the hidden determinant of treatment outcome.J Psychosom Res. 1999;47:491-5.
16. Horne R,Graupner L,Frost S,Weinman J,Wright SM,Hankins M.Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications.Soc Sci Med. 2004;59:1307-13.
17. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: 2010 Revision. 2010. See http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf(accessed March 2012).
18. Balfour L,Kowal J,Silverman A, et al.A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART.AIDS Care. 2006;18:830-8.
19. Nordqvist O,Sodergard B,Tully MP,Sonnerborg A,Lindblad AK.Assessing and achieving readiness to initiate HIV medication.Patient Educ Couns. 2006;62:21-30.
20. Fowler ME.Recognizing the phenomenon of readiness: concept analysis and case study.J Assoc Nurses AIDS Care. 1998;9:72-6.
21. Bangsberg DR,Hecht FM,Clague H, et al.Provider assessment of adherence to antiretroviral therapy.J Acquir Immune Defic Syndr. 2001;26:435-42.
22. Becker MH.Patient adherence to prescribed therapies.Med Care. 1985;23:539-55.
23. Wagner GJ,Rabkin JG.Measuring medication adherence: are missed doses reported more accurately than perfect adherence?.AIDS Care. 2000;12:405-8.
24. Martin J,Escobar I,Rubio R,Sabugal G,Cascon J,Pulido F.Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV.HIV Clin Trials. 2001;2:31-7.
25. Arnsten JH,Demas PA,Farzadegan H, et al.Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self report and electronic monitoring.Clin Infect Dis. 2001;33:1417-23.
26. Sherr L,Lampe F,Norwood S, et al.Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity.AIDS Care. 20:442-8.
27. Shuter J,Sarlo JA,Kanmaz TJ,Rode RA,Zingman BS.HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates below 95%.J Acquir Immune Defic Syndr. 2007;45:4-8.
28. Mannheimer S,Friedland G,Matts J,Child C,Chesney M.The consistency of adherence to antiretroviral therapy predicts biologic outcome for human immunodeficiency virus-infected persons in clinical trials.Clin Infect Dis. 2002;34:1115-21.
29. Farmer KC.Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.Clin Ther. 1999;21:1074-90.
30. Hill Z,Kendall C,Fernandez M.Patterns of adherence to antiretrovirals: why adherence has no simple measure.AIDS Patient Care STDS. 2003;17:519-25.
31. Sherr L,Lampe FC,Clucas C, et al.Self-reported non-adherence to ART and virological outcome in a multi-clinic UK study.AIDS Care. 2010;22:939-45.
32. Liberati A,Altman DG,Tetzlaff J, et al.The PRISMA Statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: explanation and elaboration.PLoS Med. 2009;6:1-28.
33. HigginsJGreenS. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. [updated March 2011]. The Cochrane Collaboration. 2011. See http://www.cochrane-handbook.org/(accessed July 2011).
34. ArmstrongRWatersEJacksonNGuidelines for systematic reviews of health promotion and public health interventions. Version 2. [pdf] Australia: Melbourne University. 2007. See http://ph.cochrane.org/sites/ph.cochrane.org/files/uploads/GuidelinesHP_PHreviews.pdf(accessed July 2011).
35. Mepham S,Zondi Z,Mbuyazi A,Mkhwanazi N,Newell ML.Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa.AIDS Care. 2011;23:741-7.
36. Cohn SE,Umbleja T,Mrus J,Bardeguez AD,Anderson AD,Chesney MA.Prior illicit drug use and missed prenatal vitamins predict non-adherence to antiretroviral therapy in pregnancy: adherence analysis A5084.AIDS Patient Care STDS. 2008;22:29-40.
37. Wilson TE,Ickovics JR,Fernandez MI,Koenig LJ,Walter E.Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US States.Am J Obstet Gynecol. 2001;184:1235-40.
38. Ickovics JR,Wilson TE,Royce RA, et al.Prenatal and postpartum Zidovudine adherence among pregnant women with HIV.J Acquir Immune Defic Syndr. 2002;30:311-5.
39. Mellins CA,Chu C,Malee K, et al.Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.AIDS Care. 2008;20:958-68.
40. Peltzer K,Mlambo M,Phaswana-Mafuya N,Ladzani R.Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa.Acta Pædiatrica. 2010;99:699-704.
41. Kirsten I,Sewangi J,Kunz A, et al.Adherence to combination prophylaxis for Prevention of Mother-to-Child-Transmission of HIV in Tanzania.PLoS One. 2011;6:1-9.
42. Demas PA,Thea DM,Weedon J, et al.Adherence to Zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.Women Health. 2005;42:99-115.
43. Turner BJ,Newschaffer CJ,Zhang D,Cosler L,Hauck WH.Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women.Med Care. 2000;38:911-25.
44. Delvaux T,Elul B,Ndagije F,Munyana E,Roberfroid D,Asiimwe A.Determinants of non-adherence to a single-dose nevirapine regimen for the prevention of Mother-to-Child HIV transmission in Rwanda.J Acquir Immune Defic Synd. 2009;50:223-30.
45. Laine C,Newschaffer CJ,Zhang D,Cosler L,Hauck WW,Turner BJ.Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis.Obstet Gynecol. 2000;95:167-73.
46. Bii SC,Otieno-Nyunya B,Siika A,Rotich JK.Self-reported adherence to single dose Nevirapine in the prevention of mother to child of HIV at Kitale District Hospital.East Afr Med J. 2007;84:571-6.
47. Vaz MJ,Barros SM,Palacios R, et al.HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women.Int J STD AIDS. 2007;18:28-32.
48. Albrecht S,Semrau K,Kasonde P, et al.Predictors of non-adherence to single-dose Nevirapine therapy for the prevention of mother-to-child HIV transmission.J Acquir Immune Defic Syndr. 2006;41:114-8.
49. Bardeguez AD,Lindsey JC,Shannon M, et al.Adherence to antiretrovirals among US women during and after pregnancy.J Acquir Immune Defic Syndr. 2008;48:408-17.
50. Duff P,Kipp W,Wild TC,Rubaale T,Okech-Ojony J.Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda.J Int AIDS Soc. 2010;13:1-9.
51. Ciambrone DA,Loewenthal HG,Bazerman LB,Zorilla C,Urbina B,Mitty JA.Adherence among women with HIV infection in Puerto Rico: the potential use of modified directly observed therapy (MDOT) among pregnant and postpartum women.Women Health. 2006;44:61-77.
52. McDonald K,Kirkman M.HIV-positive women in Australia explain their use and non-use of antiretroviral therapy in preventing mother-to-child transmission.AIDS Care. 2011;23:578-84.
53. Nachega JB,Knowlton AR,Deluca A, et al.Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study.J Acquir Immune Defic Syndr. 2006;43:S127-33.
54. Goujard C,Bernard N,Sohier N, et al.Impact of a patient education program on adherence to HIV medication.J Acquir Immune Defic Syndr. 2003;34:191-4.
55. Munyao P,Luchters S,Chersich MF, et al.Implementation of clinic-based modified-directly observed therapy (m-DOT) for ART: experiences in Mombasa, Kenya.AIDS Care. 2010;22:187-94.
56. Pop-Eleches C,Thirumurthy H,Habyarimana JP, et al.Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders.AIDS. 2011;25:825-34.
57. daCosta TM,Barbosa BJ,eCosta DA, et al.Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages.Int J Med Inf. 2012;81:257-69.